お知らせ • May 21
Merrimack Pharmaceuticals Files Form 15 Merrimack Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share. お知らせ • May 11
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024 Merrimack Pharmaceuticals, Inc. announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024. お知らせ • May 01
Merrimack Pharmaceuticals Intends to Voluntary Delist Class A Common Stock Pursuant to the Plan of Dissolution, on April 30, 2024, Merrimack Pharmaceuticals, Inc. notified The Nasdaq Stock Market LLC (Nasdaq") of its intention to voluntarily delist its shares of Class A common stock, par value $0.01 per share (the Common Stock") from Nasdaq and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act"). The Company currently estimates a cash dividend for the initial liquidating distribution in the range of $14.92 to $15.15 per share. Such range is an estimate and the actual cash dividend amount, which is expected to be announced on or about May 8, 2024, may fall outside of this range and is subject To Approve the Plan of Dissolution by stockholders at the Special Meeting. The Company intends to file with the SEC a Form 25 on or about May 10, 2024 to effect the delisting and deregistration of the Common Stock from Nasdaq under Section 12(b) of the Exchange Act, if the proposed liquidation and dissolution of the Company is approved by stockholders at the Special Meeting. The delisting will become effective later in May. Upon the effectiveness of the Form 25, the Company also intends to file a Form 15 with the SEC on or about May 20, 2024 to suspend the Company's reporting obligations under Sections 13 and 15(d) of the Exchange Act and deregister the Common Stock under Section 12(b) of the Exchange Act. お知らせ • Nov 10
Merrimack Pharmaceuticals, Inc. Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Merrimack Pharmaceuticals, Inc. announced that Ipsen, SA issued a press release reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a treatment of first line metastatic pancreatic ductal adenocarcinoma (mPDAC). The Ipsen press release indicates that the trial “met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and key secondary efficacy outcome of progression-free survival also showed significant improvement over the comparator arm. The safety profile of Onivyde in the NAPOLI 3 trial was consistent with those observed in the previous phase I/II mPDAC study.” Ipsen indicated in its update that it intends to file a supplemental New Drug Application with the U.S. Food and Drug Administration for Onivyde in combination with oxaliplatin plus 5- fluorouracil/leucovorin for the treatment of patients with previously untreated mPDAC following the Fast Track Designation granted in 2020. Recent Insider Transactions • Mar 22
President recently bought US$61k worth of stock On the 14th of March, Gary Crocker bought around 10k shares on-market at roughly US$6.05 per share. In the last 3 months, they made an even bigger purchase worth US$80k. Gary has been a buyer over the last 12 months, purchasing a net total of US$439k worth in shares. Recent Insider Transactions • Feb 22
President recently bought US$80k worth of stock On the 17th of February, Gary Crocker bought around 13k shares on-market at roughly US$6.17 per share. This was the largest purchase by an insider in the last 3 months. Gary has been a buyer over the last 12 months, purchasing a net total of US$399k worth in shares. Recent Insider Transactions • Jan 27
Co-Founder & Independent Director recently bought US$61k worth of stock On the 24th of January, Ulrik Nielsen bought around 14k shares on-market at roughly US$4.24 per share. This was the largest purchase by an insider in the last 3 months. This was Ulrik's only on-market trade for the last 12 months. Recent Insider Transactions • Mar 27
President recently bought US$55k worth of stock On the 24th of March, Gary Crocker bought around 9k shares on-market at roughly US$6.39 per share. This was the largest purchase by an insider in the last 3 months. Gary has been a buyer over the last 12 months, purchasing a net total of US$202k worth in shares. Is New 90 Day High Low • Mar 05
New 90-day low: US$6.44 The company is down 9.0% from its price of US$7.07 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. Is New 90 Day High Low • Feb 11
New 90-day high: US$8.70 The company is up 135% from its price of US$3.71 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. Is New 90 Day High Low • Nov 13
New 90-day low: US$3.71 The company is down 14% from its price of US$4.30 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. お知らせ • Jul 04
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from Russell Microcap Value Index Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from Russell Microcap Value Index